The considerable heterogeneity in patient age, tumor location and type of NUTM1-fusion expressed suggests that NMC may ultimately be divisible into clinically relevant sub-groups, with different clinical outcomes and treatment responses. Here, NUTM1 is linked to nut midline carcinoma.